Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity

Cardiovascular Pathology

Volumn 30, Issue , 2017, Pages 55-63

  Glass, Carolyn Kwak ^a   Mitchell, Richard N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Anthracyclines; Anthracyclinesibrosis; Cancer diagnosis; Cardiovascular toxicity; Fibrosis; Heart failure; PD 1; Tyrosine kinase inhibitors

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; CHECKPOINT KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; TRASTUZUMAB; ANTHRACYCLINE; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; TAXOID;

CANCER CHEMOTHERAPY; CARDIOTOXICITY; DRUG SAFETY; HISTOPATHOLOGY; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; NEOPLASM; PATHOLOGY;

ANTHRACYCLINES; CARDIOTOXICITY; HUMANS; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TAXOIDS; TRASTUZUMAB;

EID: 85026353542     PISSN: 10548807     EISSN: 18791336     Source Type: Journal    
DOI: 10.1016/j.carpath.2017.06.009     Document Type: Review

References (53)

1. https://www.cancer.gov.
2. Domercant, J., Polin, N., Jahangir, E., Cardio-oncology: a focused review of anthracycline-, human epidermal growth factor receptor 2 inhibitor-, and radiation-induced cardiotoxicity and management. Ochsner J 16:3 (2016), 250–256.
3. Shelburne, N., Adhikari, B., Brell, J., Davis, M., Desvigne-Nickens, P., Freedman, A., et al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities. J Natl Cancer Inst 106:9 (2014), 1–9.
4. Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2016. CA Cancer J Clin 66:1 (2016), 7–30.
5. Okwuosa, T.M., Barac, A., Burgeoning cardio-oncology programs: challenges and opportunities for early career cardiologists/faculty directors. J Am Coll Cardiol 66:10 (2015), 1193–1197.
6. Hong, R.A., Iimura, T., Sumida, K.N., Eager, R.M., Cardio-oncology/onco-cardiology. Clin Cardiol 33:12 (2010), 733–737.
7. Alarid-Escudero, F., Blaes, A.H., Kuntz, K.M., Trade-offs between efficacy and cardiac toxicity of adjuvant chemotherapy in early-stage breast cancer patients: do competing risks matter?. Breast J 23 (2017), 401–409.
8. Sun, Y., Cheng, Y., Hao, X., Wang, J., Hu, C., Han, B., et al. Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer, 16, 2016, 265.
9. Molyneux, E., Schwalbe, E., Chagaluka, G., Banda, K., Israels, T., Depani, S., et al. The use of anthracyclines in the treatment of endemic Burkitt lymphoma. Br J Haematol, 28, 2016.
10. Singal, P.K., Iliskovic, N., Li, T., Kumar, D., Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 11:12 (1997), 931–936.
11. Longhi, A., Ferrari, S., Bacci, G., Specchia, S., Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs 18:6 (2007), 737–744.
12. Lyu, Y.L., Kerrigan, J.E., Lin, C.P., Azarova, A.M., Tsai, Y.C., Ban, Y., et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane. Cancer Res 67:18 (2007), 8839–8846.
13. Lyu, Y.L., Lin, C.P., Azarova, A.M., Cai, L., Wang, J.C., Liu, L.F., Role of topoisomerase II beta in the expression of developmentally regulated genes. Mol Cell Biol 26:21 (2006), 7929–7941.
14. Von Hoff, D.D., Layard, M.W., Basa, P., Davis, H.L., Von Hoff, A.L., Rozencweig, M., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:5 (1979), 710–717.
15. Hershman, D.L., McBride, R.B., Eisenberger, A., Tsai, W.Y., Grann, V.R., Jacobson, J.S., Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkins lymphoma. J Clin Oncol 26:19 (2008), 3159–3165.
16. Cardinale, D., Colombo, A., Bacchiani, G., Tedeschi, I., Meroni, C.A., Veglia, F., et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:22 (2015), 1981–1988.
17. Wojnowski, L., Kulle, B., Schirmer, M., Schlüter, G., Schmidt, A., Rosenberger, A., et al. NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 112:24 (2005), 3754–3762.
18. Billingham, M.E., Mason, J.W., Bristow, M.R., Daniels, J.R., Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat Rep, 62, 1978, 865.
19. Volkova, M., Russell, R., Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 7:4 (2011), 214–220.
20. Leone, O., Veinot, J.P., Angelini, A., Baandrup, U.T., Basso, C., Berry, G., et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol 21:4 (2012), 245–274.
21. Stone, J.R., Basso, C., Baandrup, U.T., Bruneval, P., Butany, J., Gallagher, P.J., et al. Recommendations for processing cardiovascular surgical pathology specimens: a consensus statement from the standards and definitions Committee of the Society for Cardiovascular Pathology and the Association for European Cardiovascular Pathology. Cardiovasc Pathol 21:1 (2012), 2–16.
22. Holmes, F.A., Paclitaxel combination therapy in the treatment of metastatic breast cancer: a review. Semin Oncol 23:5 Suppl 11 (1996), 46–56.
23. Gianni, L., Dombernowsky, P., Sledge, G., Martin, M., Amadori, D., Arbuck, S.G., et al. Cardiac function following combination therapy with paclitaxel and doxorubicin: an analysis of 657 women with advanced breast cancer. Ann Oncol 12:8 (2001), 1067–1073.
24. Menna, P., Salvatorelli, E., Minotti, G., Doxorubicin degradation in cardiomyocytes. J Pharmacol Exp Ther 322:1 (2007), 408–419.
25. Baselga, J., Albanell, J., Molina, M.A., Arribas, J., Mechanism of action of trastuzumab and scientific update. Semin Oncol 28:5 Suppl 16 (2001), 4–11.
26. Mitri, Z., Constantine, T., O'Regan, R., The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract, 2012, 2012, 743193.
27. Gianni, L., Dafni, U., Gelber, R.D., Azambuja, E., Muehlbauer, S., Goldhirsch, A., et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 12:3 (2011), 236–244.
28. Wu, Y.Y., Huang, T.C., Tsai, T.N., Chen, J.H., Dai, M.S., Chang, P.Y., et al. The clinical efficacy and cardiotoxicity of fixed-dose monthly Trastuzumab in HER2-positive breast cancer: a single institutional analysis. PLoS One, 11(3), 2016, e0151112.
29. Dempsey, K.S., Chemotherapy-induced cardiotoxicity in women. Heart Fail Clin 7:3 (2011), 427–435.
30. Keefe, D.L., Trastuzumab-associated cardiotoxicity. Cancer 95:7 (2002), 1592–1600.
31. Rossi, M., Carioli, G., Bonifazi, M., Zambelli, A., Franchi, M., Moja, L., et al. Trastuzumab for HER2+ metastatic breast cancer in clinical practice: cardiotoxicity and overall survival. Eur J Cancer 52 (2016), 41–49.
32. Seidman, A., Hudis, C., Pierri, M.K., Shak, S., Paton, V., Ashby, M., et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20:5 (2002), 1215–1221.
33. Di Cosimo, S., Heart to heart with trastuzumab: a review on cardiac toxicity. Target Oncol 6:4 (2011), 189–195, 10.1007/s11523-011-0203-8.
34. Ewer, M.S., Vooletich, M.T., Durand, J.B., Woods, M.L., Davis, J.R., Valero, V., et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23:31 (2005), 7820–7826.
35. Cardinale, D., Colombo, A., Torrisi, R., Sandri, M.T., Civelli, M., Salvatici, M., et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28:25 (2010), 3910–3916.
36. El Zarrad, M.K., Mukhopadhyay, P., Mohan, N., Hao, E., Dokmanovic, M., Hirsch, D.S., et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One, 8(11), 2013, e79543.
37. Iriyama, N., Tokuhira, M., Takaku, T., Sato, E., Ishikawa, M., Nakazato, T., Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: surveillance of the CML cooperative study group. Leuk Res 54 (2017), 55–58.
38. Gandara, D.R., Riess, J.W., Kelly, K., Li, T., Mack, P.C., Lara, P.N., Evolution and increasing complexity of the therapeutic landscape in advanced non-small-cell lung cancer. Clin Lung Cancer 18:1 (2017), 1–4.
39. Ciccarese, C., Brunelli, M., Montironi, R., Fiorentino, M., Iacovelli, R., Heng, D., et al. The prospect of precision therapy for renal cell carcinoma. Cancer Treat Rev 49 (2016), 37–44.
40. Chu, T.F., Rupnick, M.A., Kerkela, R., Dallabrida, S.M., Zurakowski, D., Nguyen, L., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370:9604 (2007), 2011–2019.
41. Dahlén, T., Edgren, G., Lambe, M., Höglund, M., Björkholm, M., Sandin, F., et al. Cardiovascular events associated with use of tyrosine kinase inhibitors in chronic myeloid leukemia: a population-based cohort study. Ann Intern Med 165:3 (2016), 161–166.
42. Ghatalia, P., Je, Y., Kaymakcalan, M.D., Sonpavde, G., Choueiri, T.K., QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 112:2 (2015), 296–305.
43. Taraseviciene-Stewart, L., Kasahara, Y., Alger, L., Hirth, P., Mc, Mahon G., Waltenberger, J., Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 15:2 (2001), 427–438.
44. León-Mateos, L., Mosquera, J., Antón, Aparicio L., Treatment of sunitinib-induced hypertension in solid tumor by nitric oxide donors. Redox Biol 6 (2015), 421–425.
45. Strumberg, D., Clark, J.W., Awada, A., Moore, M.J., Richly, H., Hendlisz, A., et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 12:4 (2007), 426–437.
46. Haas, N.B., Manola, J., Uzzo, R.G., Flaherty, K.T., Wood, C.G., Kane, C., et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:10032 (2016), 2008–2016.
47. Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 12:8 (2006), 908–916.
48. Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev 12:4 (2012), 252–264.
49. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:8 (2010), 711–723.
50. Rudd, C.E., Taylor, A., Schneider, H., CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 229 (2009), 12–26.
51. Johnson, D.B., Balko, J.M., Compton, M.L., Chalkias, S., Gorham, J., Xu, Y., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375:18 (2016), 1749–1755.
52. Bayer Pharmaceuticals, http://www.univgraph.com/bayer/inserts/nexavar.pdf, 2009.
53. Grabie, N., Gotsman, I., DaCosta, R., Pang, H., Stavrakis, G., Butte, M.J., et al. Circulation 116:18 (2007), 2062–2071.